Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinlongkusu Injection is a botanical-derived small molecule therapeutic developed by Shaanxi Xida Yonghe Technology Development for the treatment of chronic hepatitis B and associated jaundice. The active pharmaceutical ingredient is gentiopicroside (also known as gentiopicrin), a secoiridoid glycoside primarily extracted from the roots of *Gentiana macrophylla* (Qin Jiao). Gentiopicroside exerts hepatoprotective effects by modulating inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), and inhibiting the NF-κB signaling pathway, thereby reducing hepatic inflammation and promoting the recovery of liver function. In clinical trials in China, it has been evaluated as a treatment for jaundice-type chronic hepatitis B, often compared against traditional therapies like Yinzhihuang Injection to assess its efficacy in reducing serum bilirubin levels and improving clinical symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gentiopicroside.